Acrivon Therapeutics EBIT

The latest EBIT for ACRV is $-87M as of March 2026. That compares with $-93M in the prior-year period — up 6.2% year over year. That is below the sector sector average of $-69M. Investors often review this figure alongside Acrivon Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ACRV's EBIT moved from $-93M to $-87M — a 6.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Acrivon Therapeutics's operating scale or balance-sheet position.

Against its sector companies, ACRV currently prints $-87M for EBIT, while the sector average sits near $-69M. That is roughly 26.7% below the sector mean. Large gaps often invite a closer look at Acrivon Therapeutics's growth, margins, and balance sheet.

A EBIT figure of $-87M for ACRV is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-69M. Explore the charts below for those layers of context.

After noting ACRV's EBIT ($-87M), review year-over-year change from $-93M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.